Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment

Published:2010-12 Issue:3 Volume:119 Page:451-456
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Blank Stephanie V.,Christos Paul,Curtin John P.,Goldman Noah,Runowicz Carolyn D.,Sparano Joseph A.,Liebes Leonard,Chen Helen X.,Muggia Franco M.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference29 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

3. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer;Wethington;Cancer,2008

4. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?;Huang;Cancer,2008

5. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup;Bookman;J Clin Oncol,2009

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials;Medical Oncology;2024-06-12

2. Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors;Current Cancer Drug Targets;2023-07

3. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial;Journal of Experimental & Clinical Cancer Research;2023-04-11

4. Targeted therapy and molecular genetics;DiSaia and Creasman Clinical Gynecologic Oncology;2023

5. Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?;Biomedicines;2022-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3